Dielectric spectroscopic studies in supercooled liquid and glassy states of Acemetacin, Brucine and Colchicine
Source abstract
Abstract
Abstract The physical and chemical instability of amorphous pharmaceuticals during storage has become a major problem for the pharmaceutical industry, as most of the pharmaceuticals including some life saving drugs are also found to be poorly water soluble. Molecular mobility is a key factor to understand the various crucial parameters that determine the stability of amorphous phase. The molecular dynamics in the supercooled liquid and glassy states of three Active Pharmaceutical Ingredients (API) Acemetacin, Brucine and Colchicine were characterized by molecular relaxation (mobility) using broadband dielectric spectroscopy (BDS) in a wide frequency range. Primary structural relaxation and intra-molecular (non Johari-Goldstein) secondary relaxation were observed above and below Tg respectively in all three title compounds. The dielectric spectra were fitted to the Havriliak-Negami (HN) function. The temperature dependence of the structural relaxation time followed Vogel-Fulcher-Tamman (VFT) equation and the secondary relaxation followed Arrhenius equation. By Coupling model (CM) prediction, the secondary relaxations in all title compounds were found to be non JG. The width of the structural relaxation peak decreases with temperature for brucine and colchicine while it increases for acemetacin. By Differential Scanning Calorimetry (DSC) experiment, we confirmed that the selelcted compounds are good glass formers and their structural properties and hydrogen bonding were studied by Fourier Transform Infrared spectroscopy (FTIR) and verified by Density Functional theory (DFT). By BDS, the parameters which describe the molecular dynamics in the supercooled and glassy states of the title compounds, like glass transition temperature (Tg) the width of the α relaxation (βKWW), the temperature dependence of α-relaxation times (τα), the fragility (m) and the activation energy of the secondary relaxation (Ea-γ), were determined. The higher values of Tg determined (307.9 K for acemetacin, 366.2 K for brucine and 374.5 K for colchicine) indicates stability of their amorphous phase at normal storage conditions. The fragility index values of the title compounds indicate intermediately fragile behaviour. The FTIR analysis of the crystalline and amorphous states of brucine, acemetacin and colchicine shows the presence of hydrogen bonding in amorphous phase of the title compounds and verified that their molecular structures were retained in the amorphous state.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Material Dynamics and Properties · Thermodynamic properties of mixtures · Crystallization and Solubility Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (78)
Show source-provided references
1. Dielectric relaxation studies and dissolution behavior of amorphous verapamil hydrochloride10.1002/jps.21877 ↗
2. Molecular dynamics of the supercooled pharmaceutical agent posaconazole studied via differential scanning calorimetry and dielectric and mechanical spectroscopies10.1021/mp4003915 ↗
3. Dielectric relaxation studies in super-cooled liquid and glassy phases of anticancerous alkaloid: brucine10.1007/s12648-017-1139-3 ↗
4. Colchicine for pericarditis
5. Physical stability of drugs after storage above and below the glass transition temperature: relationship to glass-forming ability10.1016/j.ijpharm.2015.08.101 ↗
6. Density functional theory calculation and vibrational spectral analysis of 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one10.1002/jrs.2543 ↗
7. Proceedings of the international discussion meeting on relaxations in complex systems relaxation in liquids, polymers and plastic crystals — strong/fragile patterns and problems10.1016/0022-3093(91)90266-9 ↗
8. Density-functional thermochemistry. III. The role of exact exchange10.1063/1.464913 ↗
9. Nonexponential relaxations in strong and fragile glass formers10.1063/1.466117 ↗
10. Molecular motions in amorphous ibuprofen as studied by dielectric spectroscopy10.1021/jp8040428 ↗
11. Colchicine and its analogues: recent findings10.1002/med.2610080105 ↗
12. Capaccioli · 2008 · 1520
13. On the shelf life of pharmaceutical products10.1208/s12249-012-9815-2 ↗
14. Dynamics of the amorphous and crystalline a-, c-phases of indomethacin10.1021/jp053545u ↗
15. Pressure evolution of the excess wing in a type-B glass former10.1103/PhysRevLett.91.015702 ↗
16. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update
17. Evaluation of the pharmacodynamics and pharmacokinetics of brucine following transdermal administration10.1016/j.fitote.2013.03.007 ↗
18. Amorphous powders for inhalation drug delivery10.1016/j.addr.2016.01.002 ↗
19. Chinese Pharmacopoeia Committee C · 2005
20. Colchicine in clinical medicine. A guide for internists10.1016/j.ejim.2010.09.010 ↗
21. Dinnendahl · 2003
22. F · 2003
23. Frisch · 2009
24. Analysis of recent measurements of the viscosity of glasses10.1111/j.1151-2916.1925.tb16731.x ↗
25. Johari–Goldstein relaxation and crystallization of sorbitol to ordered and disordered phases10.1063/1.1648015 ↗
26. The past, present, and future of the Johari–Goldstein relaxation10.1016/j.jnoncrysol.2010.05.105 ↗
27. Gosselin · 1984
28. Grubbs · Tetrahedron · 2004 · 60 · 711710.1016/j.tet.2004.05.124 ↗
29. Enhancement of amorphous celecoxib stability by mixing it with octaacetylmaltose: the molecular dynamics study10.1021/mp200436q ↗
30. Determination of strychnine and brucine in Strychnos nux- vomica L. by nonaqueous capillary electrophoresis10.1365/s10337-006-0734-9 ↗
31. Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetry10.1016/S0040-6031(01)00663-3 ↗
32. Characteristics and significanceofthe amorphous state in pharmaceutical systems10.1021/js9601896 ↗
33. A complex plane representation of dielectric and mechanical relaxation processes in some polymers10.1016/0032-3861(67)90021-3 ↗
34. β-molecular rearrangement process, but not an α-process, as governing the homogeneous crystal-nucleation rate in a supercooled liquid10.1246/bcsj.69.1863 ↗
35. Fatal intoxication due to brucine10.1093/anatox/35.4.248 ↗
36. Viscous Liquids and the Glass transition. II. Secondary relaxations in glasses of rigid molecules10.1063/1.1674335 ↗
37. Development of an ionogel membrane PVA/[EMIM] [SCN]with enhanced thermal stability and ionic conductivity for electrochemical application10.1016/j.molliq.2018.10.128 ↗
38. Dielectric relaxation study on tramadol monohydrate and its hydrochloride salt10.1002/jps.21799 ↗
39. Interdependence of primary and johari−goldstein secondary relaxations in glass-forming systems10.1021/jp800764w ↗
40. A.P. role of chemical structure in fragility of polymers: a qualitative picture10.1021/ma801155c ↗
41. Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines10.1016/j.kjms.2015.12.006 ↗
42. A comparison of the physical stability of amorphous felodipine and nifidipine systems10.1007/s11095-006-9047-9 ↗
43. Coordination properties of warfarin towards Pr(III) predicted from DFT and FT-IR studies10.1016/j.chemphys.2010.06.006 ↗
44. An extended coupling model description of the evolution of dynamics with time in supercooled liquids and ionic conductors10.1088/0953-8984/15/11/332 ↗
45. Classification of secondary relaxation in glass-formers based on dynamic properties10.1063/1.1630295 ↗
46. Universal behavior of dielectric responses of glass formers: role of dipole-dipole interactions10.1103/PhysRevLett.116.025702 ↗
47. FT-Raman, FT-IR and surface enhanced Raman scattering spectra of sodium salicylate10.1016/S1386-1425(01)00395-X ↗
48. The toxicity of some Strychnos species and their alkaloids10.1016/j.toxicon.2004.05.006 ↗
49. Anti-tumor effects of brucine immune-nanoparticles on hepatocellular carcinoma10.2147/IJN.S27226 ↗
50. TLC determination of strychnine and brucine of Strychnos nux vomica in ayurveda and homeopathydrugs10.1365/s10337-008-0556-z ↗
51. Colchicine in acute gout. Reassessment of risks and benefits10.1001/jama.1987.03390140090033 ↗
52. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects10.1007/BF00194404 ↗
53. Molecular mobility of amorphous s-flurbiprofen: a dielectric relaxation spectroscopy approach10.1021/mp4002188 ↗
54. Synthesis and molecular dynamics of double active pharmaceutical ingredient-benzalkonium ibuprofenate10.1016/j.molliq.2016.09.054 ↗
55. Development of ion conducting ionic liquid-based gel polymer electrolyte membrane PMMA/BMPyr.TFSI - with improved electrical, optical, thermal and structural properties10.1016/j.ssi.2017.08.012 ↗
56. Molecular dynamics in amorphous pharmaceutically important protic ionic liquid–benzalkonium chloride10.1016/j.molliq.2017.12.007 ↗
57. Dielectric spectroscopic studies of three important active pharmaceutical ingredients - clofoctol, droperidol and probucol10.1016/j.jnoncrysol.2018.10.046 ↗
58. Molecular dynamics in liquid and glassy states ofnon-steroidal anti-inflammatory drug: Ketoprofen10.1016/j.ejps.2013.03.017 ↗
59. Sailaja · Transl. Med. · 2014 · 4
60. Molecular relaxations in supercooled liquid and glassy states of amorphous quinidine: dielectric spectroscopy and density functional theory approaches10.1021/acs.jpcb.6b04242 ↗
61. Interpretation of relaxation time constants for amorphous pharmaceutical systems10.1002/(SICI)1520-6017(200003)89:3<417::AID-JPS12>3.0.CO;2-V ↗
62. Coupling between chemical reactivity and structural relaxation in pharmaceutical glasses10.1007/s11095-006-9080-8 ↗
63. Silverstein · 1991
64. Stability of amorphous pharmaceutical solids: crystal growth mechanisms and effect of polymer additives10.1208/s12248-012-9345-6 ↗
65. The dependence of viscosity upon the temperature of supercooled liquids10.1002/zaac.19261560121 ↗
66. Spectroscopic investigations of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers10.1023/A:1015147729564 ↗
67. High versus low dosing of oral colchicine for early acute gout flare: Twentyfour- hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel group, dosecomparison colchicine study10.1002/art.27327 ↗
68. Colchicine for acute gout
69. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs10.1016/j.drudis.2007.09.005 ↗
70. The law of the relation between the viscosity of liquids and the temperature
71. Binding of brucine to human serum albumin10.1016/j.molstruc.2006.06.031 ↗
72. Non-symmetrical dielectric relaxation behaviour arising from a simple empirical decay function10.1039/tf9706600080 ↗
73. Strategies to address low drug solubility in discovery and development10.1124/pr.112.005660 ↗
74. Wojnarowska · 2010 · Vol. 114 · 14815
75. The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on HepG2 cells and its possible mechanism10.1016/j.jep.2005.12.021 ↗
76. Study on the toxicity of brucine in mice
77. Analgesic and anti-inflammatory properties of brucine and brucine N-oxide extracted from seeds of Strychnos nux-vomica10.1016/S0378-8741(03)00224-1 ↗
78. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals10.1002/jps.20926 ↗